The exploratory study to determine the optimal initial dose of tyrosine kinase inhibitors including combination immunotherapy in individual patients with advanced renal cell carcinoma
Not Applicable
- Conditions
- renal cell carcinoma
- Registration Number
- JPRN-UMIN000040923
- Lead Sponsor
- Department of Urology, Graduate School of Medicine, Yamaguchi University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pharmacokinetic data, gene polymorphism, clinical efficacy, adverse events
- Secondary Outcome Measures
Name Time Method